Silence Therapeutics Plc American Depository Share (SLN)
NASDAQ: SLNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SLN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.23B
- EPS (TTM)
- -$1.05
- Dividend yield
- None
- 52-week range
- 4.19 – 19.87
- Day range
- 19.80 – 19.83
- Volume / Avg
- 399.15K / 2.41M
- Beta
- —
- Shares outstanding
- 62.20M
52-week range
SLN stock today
Silence Therapeutics Plc American Depository Share (SLN) closed at $19.81 on Nov 20, essentially unchanged from the prior close, versus the S&P 500's 3.70% decline. Trading was light, with 399.15K shares changing hands, about 17% of the average daily volume. The stock is trading at or near its 52-week high of $19.87, set on Oct 26, 2026, 372.8% above the 52-week low of $4.19.
SLN is up 225.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 213.9%. Silence Therapeutics Plc American Depository Share has posted a net loss over the last twelve months (EPS of -$1.05), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Silence Therapeutics Plc American Depository Share
Company profileSilence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D
- Headquarters
- London
- Employees
- 88
- Website
- silence-therapeutics.com
Financial highlights
Full financialsIn fiscal 2025, Silence Therapeutics Plc American Depository Share generated $559,000 in revenue, down 98.7% from fiscal 2024, the first decline in the 4 years shown. Silence Therapeutics Plc American Depository Share reported a net loss of $88.6 million, compared with a loss of $45.3 million a year earlier. Gross margin was 61.5% (down from 72.7%) and operating margin -16292.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | $559.00K | $43.26M | $31.64M | $21.66M |
| Growth | -98.71% | +36.71% | +46.12% | — |
| Net income | $-88.61M | $-45.31M | $-54.23M | $-50.33M |
| EPS (diluted) | $-0.63 | $-0.33 | $-0.49 | $-0.52 |
Analyst forecast
ForecastConsensus (5 analysts)
hold
Avg. price target
$19.75-0.30%
- Strong buy 0
- Buy 1
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.24 vs $-0.26
- Surprise
- +7.69%
SLN news
All SLN news- Silence Therapeutics plc Reports Third Quarter 2026 Financial ResultsNasdaq
- Silence Therapeutics Highlights Recent Business Achievements and Reports Third Quarter 2026 Financial ResultsBusiness Wire
- Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, GermanyBusiness Wire
- Merck KGaA, Darmstadt, Germany to Acquire Silence Therapeutics, Strengthening Rare Disease Pipeline with Innovative siRNA AssetBusiness Wire
Silence Therapeutics Plc American Depository Share peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| GENBGenerate Biomedicines Inc. | 9.54 | -8.00% | $1.23B | vs SLN |
| MNKDMannKind Corporation | 3.85 | -2.53% | $1.24B | vs SLN |
| OCULOcular Therapeutix Inc. | 5.57 | -4.95% | $1.23B | vs SLN |
| MLYSMineralys Therapeutics Inc. | 13.66 | -3.53% | $1.21B | vs SLN |
| LBRXLB Pharmaceuticals Inc | 38.85 | -2.97% | $1.26B | vs SLN |
| AMPHAmphastar Pharmaceuticals Inc. | 28.25 | +0.50% | $1.20B | vs SLN |
| GHRSGH Research PLC | 17.53 | -5.55% | $1.20B | vs SLN |
| AVLNAvalyn Pharma Inc. | 28.40 | -1.05% | $1.26B | vs SLN |
Indexes, lists and sector
Silence Therapeutics Plc American Depository Share stock FAQ
What is Silence Therapeutics Plc American Depository Share's stock price today?
SLN last traded at $19.81 as of Nov 20, 4:00 PM EST, up 0.00% on the day. Prices are delayed at least 15 minutes.
Who is Silence Therapeutics Plc American Depository Share's CEO?
Mr. Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D is the chief executive officer of Silence Therapeutics Plc American Depository Share, which has about 88 employees.
What is the SLN 52-week high?
The 52-week high for SLN is $19.87 and the 52-week low is $4.19. The stock is currently 0.3% below its high.